JP6441821B2 - 感染症の治療に用いる合成または組換えフコシル化オリゴ糖 - Google Patents
感染症の治療に用いる合成または組換えフコシル化オリゴ糖 Download PDFInfo
- Publication number
- JP6441821B2 JP6441821B2 JP2015558404A JP2015558404A JP6441821B2 JP 6441821 B2 JP6441821 B2 JP 6441821B2 JP 2015558404 A JP2015558404 A JP 2015558404A JP 2015558404 A JP2015558404 A JP 2015558404A JP 6441821 B2 JP6441821 B2 JP 6441821B2
- Authority
- JP
- Japan
- Prior art keywords
- oligosaccharides
- fucα1
- cosyl
- galβ1
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002482 oligosaccharides Chemical class 0.000 title claims description 65
- 229920001542 oligosaccharide Polymers 0.000 title claims description 59
- 238000011282 treatment Methods 0.000 title claims description 13
- 208000035473 Communicable disease Diseases 0.000 title 1
- 229930182830 galactose Natural products 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 229930182470 glycoside Natural products 0.000 claims description 24
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 17
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 206010067470 Rotavirus infection Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 8
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000369774 Norwalk-like virus Species 0.000 claims description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 150000004676 glycans Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 241001263478 Norovirus Species 0.000 description 27
- 241000702670 Rotavirus Species 0.000 description 16
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 13
- 229950006780 n-acetylglucosamine Drugs 0.000 description 13
- 208000006339 Caliciviridae Infections Diseases 0.000 description 11
- 241000700605 Viruses Species 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 150000002256 galaktoses Chemical class 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101100408360 Pisum sativum PIP20-2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 101710098620 Alpha-1,2-fucosyltransferase Proteins 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Description
図1は、ノロウイルス感染症および/またはロタウイルス感染症の治療または予防において具体例として用いられる6種のオリゴ糖を示したものである。AはFucα1−2Galβ1−3GlcNAcβ1−3Galβ1−4Glcを示し、BはGlcNAcα1−3(Fucα1−2)Galβ1−3GlcNAcβ1−3Galβ1−4Glcを示し、CはGalβ1−4(Fucα1−3)GlcNAcβ1−3Galβ1−4Glcを示し、DはGalβ1−3(Fucα1−2)Galβ1−3GlcNAcβ1−3Galβ1−4Glcを示し、EはFucα1−2Galβ1−4GlcNAcβ1−3Galβ1−4Glcを示し、FはFucα1−2Galβ1−4GalNAcβ1−3Galβ1−4Glcを示す。上記式において、Galはガラクトース単糖単位を示し、Glcはグルコース単糖単位を示し、GalNAcはN−アシル化ガラクトサミン単糖単位を示し、GlcNAcはグルコサミン単糖単位を示す。
Claims (6)
- 哺乳動物におけるノーウォーク様ウイルス感染症またはロタウイルス感染症の治療または予防に用いるためのフコシル化オリゴ糖であって、該フコシル化オリゴ糖が非還元末端および還元末端を含み、前記還元末端がβ1−4グリコシド結合で結合したガラクトース(Gal)とグルコース(Glc)とからなる第1の糖鎖単位を含み、前記非還元末端が前記還元末端の第1の糖鎖単位とβ1−3グリコシド結合で結合した第2の糖鎖単位を含み、第2の糖鎖単位がa)少なくとも1以上のフコース(Fucose)および少なくとも1以上のガラクトース(Gal)、ならびにb)少なくとも1以上のN−アセチルグルコサミン(GlcNAc)または少なくとも1以上のN−アセチルガラクトサミン(GalNAc)を含み、第2の糖鎖単位が、
GlcNAcα1−3(Fucα1−2)Galβ1−3GlcNAc、
Galβ1−3(Fucα1−2)Galβ1−3GlcNAcおよび
Fucα1−2Galβ1−4GalNAc
から選択されることを特徴とする、フコシル化オリゴ糖。 - 前記フコシル化オリゴ糖が、
GlcNAcα1−3(Fucα1−2)Galβ1−3GlcNAcβ1−3Galβ1−4Glc、
Galβ1−3(Fucα1−2)Galβ1−3GlcNAcβ1−3Galβ1−4Glcおよび
Fucα1−2Galβ1−4GalNAcβ1−3Galβ1−4Glc
の1以上から選択される、請求項1に記載の治療用または予防用のフコシル化オリゴ糖。 - 請求項2に列挙したフコシル化オリゴ糖の1つまたは2つを組み合わせて用いる、請求項2に記載の治療用または予防用のフコシル化オリゴ糖。
- 哺乳動物におけるノーウォーク様ウイルス感染症またはロタウイルス感染症の治療または予防に用いるための医薬組成物であって、請求項1〜3のいずれか1項に記載のフコシル化オリゴ糖の少なくとも1つと、薬学的に許容される担体とを含む医薬組成物。
- 請求項1〜3のいずれか1項に記載のフコシル化オリゴ糖の少なくとも1つを含む合成栄養組成物。
- ヒト以外の哺乳動物におけるノーウォーク様ウイルス感染症を治療する方法または該感染症のリスクを低減させる方法であって、それを必要とする対象に、請求項1〜3のいずれか1項に記載のフコシル化オリゴ糖、請求項4に記載の医薬組成物または請求項5に記載の合成栄養組成物を治療上有効な量投与する工程を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13156224.1 | 2013-02-21 | ||
EP13156224.1A EP2769726B1 (en) | 2013-02-21 | 2013-02-21 | Synthetic or recombinant fucosylated Oligosaccarides for use in the treatment of infections |
PCT/EP2014/052912 WO2014128057A1 (en) | 2013-02-21 | 2014-02-14 | Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016509035A JP2016509035A (ja) | 2016-03-24 |
JP6441821B2 true JP6441821B2 (ja) | 2018-12-19 |
Family
ID=47739159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015558404A Active JP6441821B2 (ja) | 2013-02-21 | 2014-02-14 | 感染症の治療に用いる合成または組換えフコシル化オリゴ糖 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9968625B2 (ja) |
EP (1) | EP2769726B1 (ja) |
JP (1) | JP6441821B2 (ja) |
KR (1) | KR102155393B1 (ja) |
CN (1) | CN105007924B (ja) |
DK (1) | DK2769726T3 (ja) |
ES (1) | ES2709599T3 (ja) |
WO (1) | WO2014128057A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015287703A1 (en) | 2014-07-09 | 2017-02-16 | Cadena Bio, Inc. | Oligosaccharide compositions and methods for producing thereof |
ES2755042T3 (es) | 2015-01-26 | 2020-04-21 | Cadena Bio Inc | Composiciones de oligosacáridos para el uso como alimento para animales y sus métodos para producirlas |
AU2016212030B2 (en) | 2015-01-26 | 2021-06-17 | Kaleido Biosciences, Inc. | Glycan therapeutics and related methods thereof |
AU2016253010B2 (en) | 2015-04-23 | 2021-06-10 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
WO2017083520A1 (en) * | 2015-11-13 | 2017-05-18 | Cadena Bio, Inc. | Animal therapeutic and feed compositions and methods of use |
RS20171030A1 (sr) | 2017-10-12 | 2019-04-30 | Pavlovic Bojan | F-fukoidani, desulfonovani f-fukoidani i njihovi derivati, desulfonovane oligo-fukoze kao inhibitori gastrointestinalnih infekcija |
AU2018431641A1 (en) * | 2018-07-12 | 2021-01-21 | N.V. Nutricia | Nutritional composition for use in the treatment of diarrhea, its preparation and method of treatment |
EP3702468A1 (en) * | 2019-03-01 | 2020-09-02 | Jennewein Biotechnologie GmbH | Fermentative production of carbohydrates by microbial cells utilizing a mixed feedstock |
KR102172667B1 (ko) * | 2020-02-05 | 2020-11-02 | 이채현 | 덱스트린 글루코노 락톤 술폰 유도체의 제조 방법 및 약제학적 조성물 이를 이용한 동물, 인간, 어류 등의 바이러스 질환 예방 및 치료제 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE225402T1 (de) * | 1990-04-16 | 2002-10-15 | Univ Pennsylvania | Saccharidzusammensetzungen, verfahren und apparate zu deren synthese |
WO1991016449A1 (en) | 1990-04-16 | 1991-10-31 | The Trustees Of The University Of Pennsylvania | Saccharide compositions, methods and apparatus for their synthesis |
US5945314A (en) * | 1997-03-31 | 1999-08-31 | Abbott Laboratories | Process for synthesizing oligosaccharides |
MXPA06006392A (es) | 2003-12-05 | 2007-03-15 | Childrens Hosp Medical Center | Composiciones de oligosacaridos y uso de estas en el tratamiento de infecciones. |
CA2757169A1 (en) * | 2009-04-13 | 2010-10-21 | Children's Hospital Medical Center | Milk oligosaccharide compositions and use thereof in treating infection in animals |
SG191395A1 (en) * | 2010-12-31 | 2013-08-30 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
-
2013
- 2013-02-21 EP EP13156224.1A patent/EP2769726B1/en active Active
- 2013-02-21 DK DK13156224.1T patent/DK2769726T3/en active
- 2013-02-21 ES ES13156224T patent/ES2709599T3/es active Active
-
2014
- 2014-02-14 WO PCT/EP2014/052912 patent/WO2014128057A1/en active Application Filing
- 2014-02-14 CN CN201480010040.2A patent/CN105007924B/zh active Active
- 2014-02-14 JP JP2015558404A patent/JP6441821B2/ja active Active
- 2014-02-14 KR KR1020157022667A patent/KR102155393B1/ko active IP Right Grant
-
2015
- 2015-08-19 US US14/830,558 patent/US9968625B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20150136057A (ko) | 2015-12-04 |
JP2016509035A (ja) | 2016-03-24 |
CN105007924A (zh) | 2015-10-28 |
ES2709599T3 (es) | 2019-04-16 |
EP2769726A1 (en) | 2014-08-27 |
WO2014128057A1 (en) | 2014-08-28 |
US9968625B2 (en) | 2018-05-15 |
CN105007924B (zh) | 2019-01-18 |
KR102155393B1 (ko) | 2020-09-14 |
US20150352133A1 (en) | 2015-12-10 |
EP2769726B1 (en) | 2018-10-31 |
DK2769726T3 (en) | 2019-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6441821B2 (ja) | 感染症の治療に用いる合成または組換えフコシル化オリゴ糖 | |
US11419885B2 (en) | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk | |
RU2769462C2 (ru) | Синергетическая выработка бутирата, связанная со сложностью смеси огм для применения у младенцев или детей младшего возраста в медицинских целях | |
EP1689348B1 (en) | Oligosaccharide compositions and use thereof in the treatment of infection | |
Newburg et al. | Human milk glycans protect infants against enteric pathogens | |
ES2895380T3 (es) | Composiciones para su uso en la prevención o tratamiento de la enterocolitis necrotizante en bebés y niños pequeños | |
RU2385714C2 (ru) | Пищевая композиция, включающая иммуноглобулины и олигосахариды | |
RU2530641C2 (ru) | Фукозиллактоза в качестве неусвояемого олигосахарида, идентичного грудному молоку, с новой функциональной пользой | |
US11559539B2 (en) | Human milk oligosaccharide for improving immune fitness | |
Gao et al. | Antiviral effects of human milk oligosaccharides: A review | |
JP2023526271A (ja) | コロナウイルスによって誘導される炎症の防止および処置のための2’-フコシルラクトース | |
US20130012472A1 (en) | Composition and methods of inhibiting gastrointestinal pathogen infection | |
EP2486931B1 (en) | Therapeutic agent for influenza virus infectious diseases | |
RU2591831C2 (ru) | Смесь неусваиваемых олигосахаридов для стимулирования иммунной системы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6441821 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |